Boeriu Estera, Borda Alexandra, Vulcanescu Dan Dumitru, Sarbu Vlad, Arghirescu Smaranda Teodora, Ciorica Ovidiu, Bratosin Felix, Marincu Iosif, Horhat Florin George
Department of Pediatrics, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square 2, 300041 Timisoara, Romania.
Department of Oncology and Haematology, "Louis Turcanu" Emergency Clinical Hospital for Children, Iosif Nemoianu Street 2, 300011 Timisoara, Romania.
Diagnostics (Basel). 2022 Jul 25;12(8):1800. doi: 10.3390/diagnostics12081800.
Infectious diseases are associated with a high morbidity and mortality rate among pediatric cancer patients undergoing treatment or receiving a transplant. Neutropenia represents a potentially fatal complication of cancer treatment and is associated with a high risk of developing bacterial infections. Although febrile neutropenia (FN) can affect both adults and children, the latter has a higher chance of infections with an unknown origin. Prompt empiric broad-spectrum antibiotic administration is collectively considered the best therapeutic approach. This review aims to analyze the latest works from the literature regarding the therapeutic strategies, schemes, and approaches and the efficacy of these in pediatric febrile neutropenia. Following PRISMA guidelines, an advanced search on PubMed, Scopus, and Cochrane Library, using the keywords "febrile neutropenia", "pediatric", "cancer", and "oncology", was performed. A total of 197 articles were found to be eligible. After screening the abstracts and excluding unfit studies, 16 articles were analyzed. There were eight retrospective studies, five prospective studies, and two clinical trials. Altogether, these studies have described around 5000 episodes of FN. The median age of the participants was 7.6 years, and the underlying condition for most of them was acute leukemia. The infectious agent could only be determined in around one-fifth of cases, from which 90% were of bacterial origin. As such, empirical broad-spectrum antibiotics are used, with the most used treatment scheme comprising third- and fourth-generation cephalosporins and antipseudomonal penicillins. In order to improve the treatment strategies of FN episodes and to successfully de-escalate treatments toward narrower-spectrum antibiotics, hospitals and clinics should increase their efforts in identifying the underlying cause of FN episodes through blood culture urine culture and viral tests, wherever infrastructure enables it.
在接受治疗或移植的小儿癌症患者中,传染病与高发病率和死亡率相关。中性粒细胞减少是癌症治疗的一种潜在致命并发症,与发生细菌感染的高风险相关。虽然发热性中性粒细胞减少(FN)可影响成人和儿童,但后者发生不明来源感染的几率更高。及时给予经验性广谱抗生素被公认为最佳治疗方法。本综述旨在分析文献中有关小儿发热性中性粒细胞减少的治疗策略、方案和方法及其疗效的最新研究。按照PRISMA指南,在PubMed、Scopus和Cochrane图书馆进行了高级检索,使用关键词“发热性中性粒细胞减少”“儿科”“癌症”和“肿瘤学”。共发现197篇文章符合条件。在筛选摘要并排除不合适的研究后,分析了16篇文章。其中有8项回顾性研究、5项前瞻性研究和2项临床试验。这些研究总共描述了约5000例FN病例。参与者的中位年龄为7.6岁,大多数人的基础疾病是急性白血病。仅在约五分之一的病例中能确定感染病原体,其中90%为细菌来源。因此,使用经验性广谱抗生素,最常用的治疗方案包括第三代和第四代头孢菌素以及抗假单胞菌青霉素。为了改进FN病例的治疗策略并成功将治疗降级为使用窄谱抗生素,医院和诊所应加大力度,在基础设施允许的情况下,通过血培养、尿培养和病毒检测来确定FN病例的潜在病因。